Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial
- 64 Downloads
Suboptimal adherence to tyrosine kinase inhibitors (TKIs) contributes to poor clinical outcomes in chronic myeloid leukemia (CML). This randomised controlled trial (RCT) aimed to evaluate the impact of a medication management service (MMS) on adherence to TKIs and clinical outcomes.
A parallel RCT was conducted in two hospitals in Malaysia, where 129 CML patients were randomised to MMS or control (usual care) groups using a stratified 1:1 block randomisation method. The 6-month MMS included three face-to-face medication use reviews, CML and TKI-related education, two follow-up telephone conversations, a printed information booklet and two adherence aids. Medication adherence (primary outcome), molecular responses and health-related quality of life (HRQoL) scores were assessed at baseline, 6th and 12th month. Medication adherence and HRQoL were assessed using medication possession ratio and the European Organisation for Research and Treatment in Cancer questionnaire (EORTC_QLQ30_CML24) respectively.
The MMS group (n = 65) showed significantly higher adherence to TKIs than the control group (n = 64) at 6th month (81.5% vs 56.3%; p = 0.002), but not at 12th month (72.6% vs 60.3%; p = 0.147). In addition, a significantly higher proportion of participants in the MMS group achieved major molecular response at 6th month (58.5% vs 35.9%; p = 0.010), but not at 12th month (66.2% vs 51.6%; p = 0.092). Significant deep molecular response was also obtained at 12th month (24.6% vs 10.9%; p = 0.042). Six out of 20 subscales of EORTC-QLQ30-CML24 were significantly better in the MMS group.
The MMS improved CML patients’ adherence to TKI as well as achieved better clinical outcomes.
Clinicaltrial.gov (ID: NCT03090477)
KeywordsMedication management service Adherence Molecular response Health-related quality-of-life Chronic myeloid leukaemia Tyrosine kinase inhibitors
The authors express their gratitude to all patients who have participated in the study. We would also like to record our appreciation to all the staff in the haematology clinics of the two hospitals in this study for their cooperation and assistance. We are grateful to Associate Professor Karuthan A/L Chinna from Taylor’s University Malaysia for his advice on statistical analysis, and to EORTC Quality of Life Group for permission granted to use the EORTC_QLQ30_CML24 questionnaire. We would also like to thank the Director General of Health Malaysia for his permission to publish this article.
Conceived and designed the study: BKT, SSC, PCB. Performed the study: BKT, SSC. Analysed the data: BKT, SSC, LCC, KMC, SB, PCB. Drafted the manuscript: BKT. Revised the manuscript critically for important intellectual content and approved the final version to be published: SSC, LCC, KMC, SB, PCB.
This study received funding from the University of Malaya under a research grant (PG057-2015A).
Compliance with ethical standards
Ethical approvals for this study was obtained from the Medical Research and Ethics Committee (MREC) Ministry of Health Malaysia (Ref. No. NMRR-14-1466-23315 [IIR] dated 7 September 2015) and Medical Ethics Committee of University Malaya Medical Centre (Ref. No. 201411-802 dated 2 November 2014).
Conflict of interest
The authors declare that they have no conflicts of interest.
- 2.Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood. 126(1):42–49CrossRefGoogle Scholar
- 5.Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 117(14):3733–3736CrossRefGoogle Scholar
- 6.Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388CrossRefGoogle Scholar
- 10.Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. PharmacoEconomics. 25(6):481–496CrossRefGoogle Scholar
- 13.Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E et al (2013) Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes 11:167CrossRefGoogle Scholar
- 17.Leader A, Benyamini N, Gafter-Gvili A, Dreyer J, Calvarysky B, Amitai A et al (2018) Effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): a quasi-experimental pre-post intervention multicenter pilot study. Clin Lymphoma Myeloma Leuk 18(11):e449–ee61CrossRefGoogle Scholar
- 21.Tan BK, Tan SB, Chen LC, Chang KM, Chua SS, Balashanker S, Kamarul Jaman HNB, Edmund SC, Bee PC (2017) Medication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative study. Patient Prefer Adher 11:1027–1034CrossRefGoogle Scholar
- 23.Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122(6):872–884CrossRefGoogle Scholar
- 24.Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo D, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H (2018) Chronic myeloid leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16(9):1108–1135CrossRefGoogle Scholar
- 25.Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23(3):825–836CrossRefGoogle Scholar
- 31.Gomez-Almaguer D, Saldana-Vazquez R, Tarin-Arzaga L, Herrera-Rojas MA, Vazquez-Mellado de Larracoechea A, Cantu-Rodriguez OG et al (2016) Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure. Hematology (Amsterdam, Netherlands) 21(7):411–414Google Scholar